Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Pharma
Akeso details ivonescimab's 1st overall survival win
The addition of ivonescimab to chemotherapy reduced the risk of death by 26% in patients with EGFR-mutated NSCLC who had tried an EGFR inhibitor.
Angus Liu
Nov 7, 2025 11:30am
Keytruda, Padcev cut risk of death by 50% in MIBC patient subset
Oct 18, 2025 10:30am
ESMO: Merck lays out Keytruda's landmark win in ovarian cancer
Oct 18, 2025 10:30am
Merck scores FDA approval for subcutaneous Keytruda
Sep 19, 2025 4:54pm
Editor's Corner—Summit must submit to Big Pharma, stat
Sep 10, 2025 2:50pm
Roche touts Tecentriq biomarker win in bladder cancer
Aug 18, 2025 4:17pm
